Palisade Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Palisade Bio

25/03/2025 13:31

Palisade Bio Inc PALI.OQ reported a quarterly adjusted loss of $1.55​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-6.45.  The mean expectation of three analysts for the quarter was for a loss of $1.99 per share. Wall Street expected results to range from $-2.76 to -81 cents per share.

Reported revenue was zero​; analysts expected zero.

Palisade Bio Inc's reported EPS for the quarter was a loss of $1.55​.

The company reported a quarterly loss of $3.34 million.

Palisade Bio Inc shares had fallen by 57.5% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 11.2% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Palisade Bio Inc is $14.00

This summary was machine generated from LSEG data March 25 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-1.99
-1.55
Beat
Sep. 30 2024
-3.35
-2.32
Beat
Jun. 30 2024
-2.93
-3.32
Missed
Mar. 31 2024
-4.80
-4.59
Beat